Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
China Companies Business Strategies

China’s Insatiable Appetite For Latest Therapies Prompts Ex-Exec To Take New Journey

Neukio Sees NK Promise

  • Interviews

Executive Summary

After immuno-oncology, cell therapies such as CAR-Ts have attracted millions of dollars of funding in China and one former executive is now sailing into the largely uncharted waters of natural killer cells.

You may also be interested in...



Asia Deal Watch: Incyte Inks Chinese Marketing Partnership With InnoCare For Monjuvi

Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.

Oncology, Cell Therapy Developers Bag $175m In China

Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.

Mixed Results For China’s First Home-Grown COVID Antiviral

A preliminary analysis of Russian Phase III results for azvudine, China's first home-grown antiviral for COVID-19, shows it reached two primary endpoints, but a separate Chinese study produced mixed results.

Table

View full table

Topics

Related Companies

Tags:
China Companies Business Strategies
Latest News

Bone Gets Lucky Break At Last With Medsenic Merger

Shionogi Reveals Strategy For COVID-19 Drug Xocova

Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC

Patent Settlements and Medicare Negotiation: What Leverage Does Pharma Have To ‘Game’ Price Reform?

See All
UsernamePublicRestriction

Register

SC144954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By